Show simple item record

dc.contributor.authorWinfield, JMen_US
dc.contributor.authorTunariu, Nen_US
dc.contributor.authorRata, Men_US
dc.contributor.authorMiyazaki, Ken_US
dc.contributor.authorJerome, NPen_US
dc.contributor.authorGermuska, Men_US
dc.contributor.authorBlackledge, MDen_US
dc.contributor.authorCollins, DJen_US
dc.contributor.authorde Bono, JSen_US
dc.contributor.authorYap, TAen_US
dc.contributor.authordeSouza, NMen_US
dc.contributor.authorDoran, SJen_US
dc.contributor.authorKoh, D-Men_US
dc.contributor.authorLeach, MOen_US
dc.contributor.authorMessiou, Cen_US
dc.contributor.authorOrton, MRen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2017-03-24T14:45:59Z
dc.date.issued2017-07en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28301311en_US
dc.identifier.citationRadiology, 2017, 284 (1), pp. 88 - 99en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/513
dc.identifier.eissn1527-1315en_US
dc.identifier.doi10.1148/radiol.2017161965en_US
dc.description.abstractPurpose To assess the repeatability of apparent diffusion coefficient (ADC) estimates in extracranial soft-tissue diffusion-weighted magnetic resonance imaging across a wide range of imaging protocols and patient populations. Materials and Methods Nine prospective patient studies and one prospective volunteer study, performed between 2006 and 2016 with research ethics committee approval and written informed consent from each subject, were included in this single-institution study. A total of 141 tumors and healthy organs were imaged twice (interval between repeated examinations, 45 minutes to 10 days, depending the on study) to assess the repeatability of median and mean ADC estimates. The Levene test was used to determine whether ADC repeatability differed between studies. The Pearson linear correlation coefficient was used to assess correlation between coefficient of variation (CoV) and the year the study started, study size, and volumes of tumors and healthy organs. The repeatability of ADC estimates from small, medium, and large tumors and healthy organs was assessed irrespective of study, and the Levene test was used to determine whether ADC repeatability differed between these groups. Results CoV aggregated across all studies was 4.1% (range for each study, 1.7%-6.5%). No correlation was observed between CoV and the year the study started or study size. CoV was weakly correlated with volume (r = -0.5, P = .1). Repeatability was significantly different between small, medium, and large tumors (P < .05), with the lowest CoV (2.6%) for large tumors. There was a significant difference in repeatability between studies-a difference that did not persist after the study with the largest tumors was excluded. Conclusion ADC is a robust imaging metric with excellent repeatability in extracranial soft tissues across a wide range of tumor sites, sizes, patient populations, and imaging protocol variations. Online supplemental material is available for this article.en_US
dc.format.extent88 - 99en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectDiffusion Magnetic Resonance Imagingen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectImage Enhancementen_US
dc.subjectMaleen_US
dc.subjectProspective Studiesen_US
dc.subjectReproducibility of Resultsen_US
dc.subjectSoft Tissue Neoplasmsen_US
dc.titleExtracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-06-28en_US
rioxxterms.versionofrecord10.1148/radiol.2017161965en_US
rioxxterms.licenseref.startdate2017-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfRadiologyen_US
pubs.issue1en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume284en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamMagnetic Resonanceen_US
dc.contributor.icrauthorTunariu, Ninaen_US
dc.contributor.icrauthorWinfield, Jessicaen_US
dc.contributor.icrauthorYap, Timothyen_US
dc.contributor.icrauthorKoh, Dow-Muen_US
dc.contributor.icrauthorBlackledge, Matthewen_US
dc.contributor.icrauthorLeach, Martinen_US
dc.contributor.icrauthorDe Bono, Johannen_US
dc.contributor.icrauthordeSouza, Nanditaen_US
dc.contributor.icrauthorDoran, Simonen_US
dc.contributor.icrauthorMessiou, Christinaen_US
dc.contributor.icrauthorMarsden,en_US
dc.contributor.icrauthorMiyazaki, Keikoen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/